Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj

Percentage of subjects whose EASI decreased by 50% or more at each evaluation visit compared to the baseline (EASI-50)

Time frame: for 5 years

Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 75% at each visit (EASI-75)

Time frame: for 5 years

Rate of change and Change in EASI from baseline

EASI range is from 0 (clear) to 72 (severe)

Time frame: for 5 years

Percentage of subjects whose Investigator's Global Assessment (IGA) score at each visit is 0 or 1

Time frame: for 5 years

Percentage of subjects whose IGA at each visit is 0 or 1, or improved to 2 or higher

Time frame: for 5 years

Percentage of subjects whose SCORing Atopic Dermatitis (SCORAD) INDEX was decreased from baseline by more than 50% at each visit (SCORAD-50)

Time frame: for 5 years

Rate of change and Change in SCORAD index from baseline at each visit

SCORAD index range is from 0 (clear) to 103 (severe)

Time frame: for 5 years

Change and rate of change in Body Surface Area (BSA)

Time frame: for 5 years